What is Trillium Therapeutics Inc (TRIL) stock price today?
Trillium Therapeutics Inc.'s stock symbol is TRIL and currently trades under NASDAQ. It’s current price per share is approximately $ 17.29. What are your Trillium Therapeutics Inc. (TRIL) stock predictions?
What is the upside for Trillium Therapeutics'stock?
Their forecasts range from $18.50 to $25.00. On average, they anticipate Trillium Therapeutics' stock price to reach $20.30 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price.
What is Trillium Therapeutics'mailing address?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
What does a hold rating mean for Trillium Therapeutics (TRIL)?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares. View analyst ratings for Trillium Therapeutics or view top-rated stocks. When is Trillium Therapeutics' next earnings date?
Is Trillium Therapeutics good stock to buy?
Consensus Rating. Trillium Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
What happened to my Trillium Therapeutics stock?
Trillium's common shares will be delisted from the Toronto Stock Exchange on or before November 19, 2021.
Will Trillium Therapeutics stock go up?
Trillium Therapeutics Inc quote is equal to 18.440 USD at 2022-07-04. Based on our forecasts, a long-term increase is expected, the "TRIL" stock price prognosis for 2026-11-16 is 51.043 USD. With a 5-year investment, the revenue is expected to be around +176.8%. Your current $100 investment may be up to $276.8 in 2027.
Is C4 Therapeutics a good stock to buy?
C4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.
Why did Pfizer buy Trillium?
Trillium is now a completely owned Pfizer subsidiary and the deal is claimed to boost the latter's oncology portfolio by adding advanced, experimental immuno-therapeutics to treat haematological cancers. With the acquisition, Pfizer gained rights to two lead molecules of Trillium, TTI-622 and TTI-621.
Did Pfizer buy Trillium?
(NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
Will C4 Therapeutics stock go up?
Stock Price Forecast The 12 analysts offering 12-month price forecasts for C4 Therapeutics Inc have a median target of 21.00, with a high estimate of 84.00 and a low estimate of 10.00. The median estimate represents a +112.55% increase from the last price of 9.88.
Why is Trillium stock up?
Pfizer Nabs Cancer Deal For $2.26 Billion, Helping Trillium Stock Skyrocket. Pfizer stock rose Monday on its $2.26 billion plan to acquire Trillium Therapeutics (TRIL) in a cancer mashup that also helped TRIL stock to skyrocket. The deal adds to Pfizer's (PFE) pipeline of blood cancer treatments.
How do I invest in Trillium?
How to buy TrilliumCheck CoinMarketCap to see where you can buy Trillium and with which currencies. For each cryptocurrency, CoinMarketCap provides a list of purchasing options (also known as market pairs). ... Pick a platform to make your purchase. ... Make the purchase on your chosen platform.
Should I buy or sell Trillium Therapeutics stock right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 5 hol...
What is Trillium Therapeutics' stock price forecast for 2022?
5 analysts have issued 12 month target prices for Trillium Therapeutics' stock. Their forecasts range from $18.50 to $18.50. On average, they predi...
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings results on Thursday, November, 18th. The biotechnology company reported ($0....
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the following people: Jan Skvarka , President, Chief Executive Officer & Director James T. Parson...
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Maravai LifeSciences (MRVI) , Legend Biotech (LEGN) , Sarepta Therapeutics (SRP...
What other stocks do shareholders of Trillium Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmac...
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately $18.44.
How much money does Trillium Therapeutics make?
Trillium Therapeutics (NASDAQ:TRIL) has a market capitalization of $1.94 billion and generates $150 thousand in revenue each year. The biotechnolog...
Is Trillium Therapeutics a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 2 hol...
Is Trillium Therapeutics a good dividend stock?
Trillium Therapeutics pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%.
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the following people: Calvin R. Stiller M.D. , Independent Chairman of the Board Niclas Stiernhol...
What other stocks do shareholders of Trillium Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FU...
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
How do I buy shares of Trillium Therapeutics?
Shares of TR and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian...
What is Trillium Therapeutics' official website?
The official website for Trillium Therapeutics is www.trilliumtherapeutics.com .
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada . The company can be reached via phone at +1-416-5950627 .
What is Trillium Therapeutics?
Where is Trillium Therapeutics located?
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Is Trillium Therapeutics a buy right now?
and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
When is Trillium Therapeutics' next earnings date?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Trillium Therapeutics stock.
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for Trillium Therapeutics.
Is Trillium Therapeutics a good dividend stock?
Trillium Therapeutics Inc (TSE:TR) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.23) EPS for the quarter, meeting analysts' consensus estimates of ($0.23). View Trillium Therapeutics' earnings history.
What other stocks do shareholders of Trillium Therapeutics own?
Trillium Therapeutics pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%.
What is Trillium Therapeutics' stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), (ECA), ConocoPhillips (COP), Canadian Natural Resources (CNQ), bluebird bio (BLUE) and Biogen (BIIB)..
How do I buy shares of Trillium Therapeutics?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
About TRIL
Shares of TR and other Canadian stocks can be purchased through an online brokerage account.
Stats
Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides.
About Trillium Therapeutics Inc
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
Golden Star Signal
Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers.
